CCND1 and esophageal squamous cell carcinoma: Our findings provided rationale to potentially extend the application of CYH33 for the treatment of ESCC with amplified CCND1. Nevertheless, these findings in ESCC cells and PDXS need to be verified in clinical settings, which might be fulfilled by the future studies with the data obtained from the ongoing clinical trials of CYH33 in ESCC patients (NCT03544905).